278 related articles for article (PubMed ID: 33947641)
1. Reply to: "Liver fibrosis and adverse outcomes in COVID-19".
Ruiz-Margáin A; Campos-Murguía A; González-Regueiro JA; Román-Calleja BM; Delint DK; Macías-Rodríguez RU
Dig Liver Dis; 2021 Jul; 53(7):800. PubMed ID: 33947641
[No Abstract] [Full Text] [Related]
2. Liver fibrosis and adverse outcomes in COVID-19.
Huang J
Dig Liver Dis; 2021 Jul; 53(7):799. PubMed ID: 33994131
[No Abstract] [Full Text] [Related]
3. Reply to: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).
López-Mendez I; Castro-Narro G
Ann Hepatol; 2021; 22():100326. PubMed ID: 33582320
[No Abstract] [Full Text] [Related]
4. Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19".
Iavarone M; D'Ambrosio R; Lampertico P;
J Hepatol; 2020 Dec; 73(6):1570-1571. PubMed ID: 32771429
[No Abstract] [Full Text] [Related]
5. Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
Iavarone M; D'Ambrosio R; Lampertico P
Gut; 2021 Sep; 70(9):1798-1799. PubMed ID: 33028665
[No Abstract] [Full Text] [Related]
6. COVID-19 in patients with cirrhosis: understanding adverse impact.
Sharma S; Elhence A; Vaishnav M; Kumar R; Shalimar
Gut; 2021 Jul; 70(7):1409. PubMed ID: 32826307
[No Abstract] [Full Text] [Related]
7. SARS-CoV-2 infection in patients with a normal or abnormal liver.
Cabibbo G; Rizzo GEM; Stornello C; Craxì A
J Viral Hepat; 2021 Jan; 28(1):4-11. PubMed ID: 33190321
[TBL] [Abstract][Full Text] [Related]
8. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19.
Ibáñez-Samaniego L; Bighelli F; Usón C; Caravaca C; Fernández Carrillo C; Romero M; Barreales M; Perelló C; Madejón A; Marcos AC; Albillos A; Fernández I; García-Samaniego J; Calleja JL; Bañares R
J Infect Dis; 2020 Aug; 222(5):726-733. PubMed ID: 32563190
[TBL] [Abstract][Full Text] [Related]
9. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).
Li X
Ann Hepatol; 2021; 22():100295. PubMed ID: 33253894
[No Abstract] [Full Text] [Related]
10. Letter regarding "High rates of 30-day mortality in patients with cirrhosis and COVID-19".
Medhat MA; El Kassas M
J Hepatol; 2020 Dec; 73(6):1569-1570. PubMed ID: 32574577
[No Abstract] [Full Text] [Related]
11. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
12. Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis.
Xiao Y; Pan H; She Q; Wang F; Chen M
Lancet Gastroenterol Hepatol; 2020 Jun; 5(6):528-529. PubMed ID: 32197093
[No Abstract] [Full Text] [Related]
13. The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research.
Gao F; Huang ZM
J Hepatol; 2020 Dec; 73(6):1568-1569. PubMed ID: 32574579
[No Abstract] [Full Text] [Related]
14. Clinically significant portal hypertension in cirrhosis patients with COVID-19: Clinical characteristics and outcomes.
Liu F; Long X; Ji G; Zhang B; Zhang W; Zhang Z; Chen X
J Infect; 2020 Aug; 81(2):e178-e180. PubMed ID: 32562796
[No Abstract] [Full Text] [Related]
15. Trends in cirrhosis hospitalizations during the COVID-19 pandemic.
Gaspar R; Liberal R; Branco CC; Macedo G
Dig Liver Dis; 2020 Sep; 52(9):942-943. PubMed ID: 32680758
[No Abstract] [Full Text] [Related]
16. Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection".
Mungmunpuntipantip R; Wiwanitkit V
Ann Hepatol; 2021; 25():100360. PubMed ID: 34119682
[No Abstract] [Full Text] [Related]
17. The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC).
Kim DJ; Jeong WI; Tsukamoto H; Gao B
Clin Mol Hepatol; 2020 Oct; 26(4):584-585. PubMed ID: 33053933
[No Abstract] [Full Text] [Related]
18. Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review.
Saba L; Gerosa C; Fanni D; Marongiu F; La Nasa G; Caocci G; Barcellona D; Balestrieri A; Coghe F; Orru G; Coni P; Piras M; Ledda F; Suri JS; Ronchi A; D'Andrea F; Cau R; Castagnola M; Faa G
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12609-12622. PubMed ID: 33336781
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis.
Del Zompo F; De Siena M; Ianiro G; Gasbarrini A; Pompili M; Ponziani FR
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):13072-13088. PubMed ID: 33378061
[TBL] [Abstract][Full Text] [Related]
20. Let's not forget our COVID-19-free cirrhotic patients!
Viganò M; Carbone M
Liver Int; 2020 Jun; 40(6):1508-1509. PubMed ID: 32329551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
